DE602006010111D1 - Pharmazeutische formulierung zur behandlung von osteoarthritis mit clodronsäure und hyaluronsäure - Google Patents

Pharmazeutische formulierung zur behandlung von osteoarthritis mit clodronsäure und hyaluronsäure

Info

Publication number
DE602006010111D1
DE602006010111D1 DE602006010111T DE602006010111T DE602006010111D1 DE 602006010111 D1 DE602006010111 D1 DE 602006010111D1 DE 602006010111 T DE602006010111 T DE 602006010111T DE 602006010111 T DE602006010111 T DE 602006010111T DE 602006010111 D1 DE602006010111 D1 DE 602006010111D1
Authority
DE
Germany
Prior art keywords
acid
osteoarthritis
treatment
pharmaceutical formulation
hyaluronic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006010111T
Other languages
German (de)
English (en)
Inventor
Sergio Rosini
Silvia Trasciatti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abiogen Pharma SRL
Original Assignee
Abiogen Pharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abiogen Pharma SRL filed Critical Abiogen Pharma SRL
Publication of DE602006010111D1 publication Critical patent/DE602006010111D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
DE602006010111T 2005-12-29 2006-12-21 Pharmazeutische formulierung zur behandlung von osteoarthritis mit clodronsäure und hyaluronsäure Active DE602006010111D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT002515A ITMI20052515A1 (it) 2005-12-29 2005-12-29 Formulazione farmaceutica per il trattamento della osteoartrite
PCT/EP2006/012367 WO2007073921A1 (en) 2005-12-29 2006-12-21 Pharmaceutical formulation for the treatment of osteoarthritis containing clodronic acid and hyaluronic acid

Publications (1)

Publication Number Publication Date
DE602006010111D1 true DE602006010111D1 (de) 2009-12-10

Family

ID=36648609

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006010111T Active DE602006010111D1 (de) 2005-12-29 2006-12-21 Pharmazeutische formulierung zur behandlung von osteoarthritis mit clodronsäure und hyaluronsäure

Country Status (20)

Country Link
US (4) US20090042833A1 (https=)
EP (1) EP1976538B1 (https=)
JP (1) JP2009522218A (https=)
KR (2) KR20140107651A (https=)
AT (1) ATE446763T1 (https=)
AU (1) AU2006331019B2 (https=)
CA (1) CA2646974C (https=)
CY (1) CY1109541T1 (https=)
DE (1) DE602006010111D1 (https=)
DK (1) DK1976538T3 (https=)
ES (1) ES2333615T3 (https=)
IT (1) ITMI20052515A1 (https=)
NO (1) NO340794B1 (https=)
NZ (1) NZ569420A (https=)
PL (1) PL1976538T3 (https=)
PT (1) PT1976538E (https=)
RU (1) RU2414908C2 (https=)
SI (1) SI1976538T1 (https=)
WO (1) WO2007073921A1 (https=)
ZA (1) ZA200805598B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120208757A1 (en) * 2010-10-07 2012-08-16 Excel Med, Llc Use of hyaluronan for promoting angiogenesis
JP6683700B2 (ja) 2014-11-07 2020-04-22 株式会社エキソステムテックＥｘｏｓｔｅｍｔｅｃｈ Ｃｏ．，Ｌｔｄ． 幹細胞由来のエキソソームを含有する脂肪細胞分化誘導、または脂肪組織の再生用組成物の製造方法
KR101706642B1 (ko) 2015-02-04 2017-02-17 주식회사 엑소스템텍 연골세포로 분화되고 있는 줄기세포로부터 추출된 엑소좀을 포함하는 연골세포 분화 유도 또는 연골조직 재생용 조성물
IT201600123773A1 (it) 2016-12-06 2018-06-06 Abiogen Pharma Spa Composizione per il trattamento dell’osteoartrosi
IT202100023894A1 (it) * 2021-09-16 2023-03-16 Professional Derma Sa Composizione per utilizzo in campo ortopedico
EP4450062A1 (en) 2023-04-20 2024-10-23 Abiogen Pharma S.p.A. Composition for the treatment of osteoarthrosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1187828B (it) * 1985-05-24 1987-12-23 Gentili Ist Spa Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi
JP2001253827A (ja) * 2000-02-15 2001-09-18 Pfizer Prod Inc 骨粗鬆症を治療するための組成物および方法
JP3923800B2 (ja) * 2000-05-05 2007-06-06 エフ．ホフマン−ラ ロシュ アーゲー ビスホスホン酸またはそれらの塩を含む、皮下投与のためのゲル様医薬組成物
BR0310087A (pt) * 2002-05-17 2005-08-16 Wyeth Corp Veìculos sólidos injetáveis para ácido hialurÈnico para aplicação de proteìnas osteogênicas
KR100648515B1 (ko) * 2004-05-04 2006-11-27 (주)아모레퍼시픽 비스포스포네이트-함유 고분자 미립구를 포함하는 골-관련질환 치료 또는 예방용 서방 효과를 갖는 주사제

Also Published As

Publication number Publication date
US20200147126A1 (en) 2020-05-14
EP1976538B1 (en) 2009-10-28
WO2007073921A1 (en) 2007-07-05
RU2414908C2 (ru) 2011-03-27
RU2008126108A (ru) 2010-01-10
ATE446763T1 (de) 2009-11-15
US20180185407A1 (en) 2018-07-05
NO20082848L (no) 2008-08-27
ITMI20052515A1 (it) 2007-06-30
ES2333615T3 (es) 2010-02-24
AU2006331019A2 (en) 2009-01-22
PT1976538E (pt) 2009-12-07
KR101470608B1 (ko) 2014-12-09
DK1976538T3 (da) 2010-01-11
JP2009522218A (ja) 2009-06-11
ZA200805598B (en) 2009-11-25
SI1976538T1 (sl) 2010-01-29
NO340794B1 (no) 2017-06-19
US20140371170A1 (en) 2014-12-18
US20090042833A1 (en) 2009-02-12
US9943540B2 (en) 2018-04-17
HK1123986A1 (en) 2009-07-03
AU2006331019B2 (en) 2012-03-22
PL1976538T3 (pl) 2010-03-31
CA2646974C (en) 2013-06-11
AU2006331019A1 (en) 2007-07-05
KR20080082657A (ko) 2008-09-11
CY1109541T1 (el) 2014-08-13
NZ569420A (en) 2010-05-28
EP1976538A1 (en) 2008-10-08
CA2646974A1 (en) 2007-07-05
KR20140107651A (ko) 2014-09-04

Similar Documents

Publication Publication Date Title
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
MY143795A (en) Tetrahydropyridoindole derivatives
WO2008046003A3 (en) Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
BRPI0507680A (pt) partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas
BRPI0511478A (pt) composições de vidro como aditivo antimicrobiano para materiais dentários
DE502004002571D1 (de) Substituierte 3-pyrrolidin-indol-derivate
UY31673A1 (es) "derivados heterocíclicos de urea y métodos de uso de los mismos-211"
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
BRPI0511616A (pt) compostos
CY1108794T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
DE60313004D1 (de) Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination
CL2008003659A1 (es) Compuestos derivados de 6-(4-bencilpiperazin-1-il)pirimidin-4-ona, moduladores de la enzima estearoil-coa-desaturasa 1; procedimiento de preparacion; composicin farmaceutica; y uso en el tratamiento y profilaxis de la obesidad.
TW200738659A (en) Novel compounds
NO20082848L (no) Farmasoytisk formulering for behandling av osteoartritt inneholdende klodronsyre og hyaluronsyre
SE0301320D0 (sv) Positive modulators of nicotinic acetylcholine receptors
ATE457027T1 (de) Substituierte 1,4,8-triazaspiroä4.5 decan-2-on- verbindungen zur behandlung von fettsucht
DE502006004182D1 (de) Substituierte 5,6,7,8-tetrahydro-imidazoä1 ,2-aüpyridin-2-ylamin-verbindungen und deren verwendung zur herstellung von arzneimitteln
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
ATE475408T1 (de) Formulierungen von tipifarnib zur intravenösen verabreichung
WO2007068473A3 (en) Organic compounds
ATE487492T1 (de) Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit
EA200700413A1 (ru) Ариламинкетоны, способ их получения, фармацевтические композиции, содержащие их, и их применение
CY1108225T1 (el) Παραγωγα τετραϋδροπυριδοϊνδολιου

Legal Events

Date Code Title Description
8364 No opposition during term of opposition